Response Genetics to Net $2.2M in Placement of Common Stock | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics today said that it will sell 1,175,512 shares of its common stock to certain institutional investors, raising net proceeds of around $2.2 million.

The Los Angeles-based molecular diagnostics firm said that it would sell the shares at a price of $1.99 each through a registered direct offering to certain, unnamed investors. It expects to close the offering tomorrow.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.